View Older Stories View More Recent Stories

Oct 29, 2025 09:59AM Incyte (INCY) PT Raised to $101 at TD Cowen; 'Q3 Beats Across All Franchises'
Oct 28, 2025 03:29PM Incyte (INCY) PT Raised to $84 at Oppenheimer
Oct 28, 2025 10:31AM Incyte (INCY) PT Raised to $109 at BofA Securities
Oct 28, 2025 07:02AM Incyte (INCY) Tops Q3 EPS by 67c; raises guidance
Oct 14, 2025 09:46AM Incyte (INCY) PT Raised to $76 at UBS
Oct 8, 2025 02:56AM Oppenheimer Downgrades Incyte (INCY) to Perform
Oct 3, 2025 04:03PM Incyte appoints Thomas Tray as principal financial officer
Sep 24, 2025 05:03AM Incyte (INCY) PT Raised to $81 at RBC Capital
Sep 22, 2025 04:39AM Incyte (INCY) PT Raised to $115 at Stifel
Sep 18, 2025 04:15AM Citizens JMP Reiterates Market Perform Rating on Incyte (INCY)
Sep 3, 2025 09:15AM Incyte launches awareness campaign for hidradenitis suppurativa patients
Aug 1, 2025 03:59AM Barclays Starts Incyte (INCY) at Overweight
Jul 30, 2025 08:29AM Incyte (INCY) PT Raised to $60 at BMO Capital
Jul 30, 2025 07:59AM Incyte (INCY) PT Raised to $72 at RBC Capital
Jul 29, 2025 04:12PM Incyte (INCY) PT Raised to $79 at Truist Securities
Jul 29, 2025 04:06PM Incyte (INCY) PT Raised to $89 at TD Cowen
Jul 29, 2025 07:02AM Incyte (INCY) Misses Q2 EPS by 140c
Jul 24, 2025 05:02PM Incyte to present cancer drug data at ESMO Congress 2025
Jul 15, 2025 09:44AM Incyte (INCY) PT Raised to $62 at UBS
Jun 26, 2025 12:27PM William Blair Comments on Incyte (INCY) CEO Transition
Jun 26, 2025 10:36AM Citi Comments Incyte (INCY) New CEO
Jun 26, 2025 09:45AM Incyte (INCY) new CEO sparks chatter
Jun 26, 2025 09:18AM Incyte (INCY) CEO change timing 'feels right' - Stifel
Jun 26, 2025 07:30AM Incyte (INCY) Appoints Bill Meury as Next CEO
Jun 20, 2025 04:31PM Incyte (INCY) announces that FDA extends review for Ruxolitinib cream
Jun 18, 2025 03:39PM Incyte (INCY) Announces FDA Approval of Monjuvi in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Jun 18, 2025 03:38PM FDA approves Incyte's tafasitamab-cxix for relapsed or refractory follicular lymphoma
Jun 16, 2025 07:55AM Incyte (INCY): Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Jun 16, 2025 06:11AM Oppenheimer Reiterates Outperform Rating on Incyte (INCY)
Jun 16, 2025 04:48AM Incyte (INCY) PT Raised to $82 at Jefferies
Jun 16, 2025 03:09AM Stifel Upgrades Incyte (INCY) to Buy
Jun 12, 2025 12:05PM Incyte (INCY) and Specialised Therapeutics expand partnership, add to oncology portfolio
Jun 11, 2025 09:22AM UBS Reiterates Neutral Rating on Incyte (INCY)
Jun 4, 2025 08:50AM Stifel Reiterates Hold Rating on Incyte (INCY)
Jun 4, 2025 06:29AM TD Cowen Reiterates Buy Rating on Incyte (INCY)
Jun 3, 2025 03:53PM JPMorgan Reiterates Neutral Rating on Incyte (INCY)
Jun 3, 2025 01:01PM Citi Reiterates Buy Rating on Incyte (INCY)
Jun 3, 2025 12:10PM BMO Capital weighs in on Incyte (INCY) following mCALR antibody data
Jun 3, 2025 10:30AM Incyte (INCY) Announces Multiple Presentations
Jun 2, 2025 09:50AM UBS Reiterates Neutral Rating on Incyte (INCY)
May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 15, 2025 02:30PM Incyte (INCY) Announces FDA Approval of Zynyz Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
May 14, 2025 08:03AM Incyte (INCY) and Novartis (NVS) entered into settlement agreement
Apr 29, 2025 11:30AM Incyte (incy) PT Raised to $89 at BofA Securities
Apr 29, 2025 07:00AM Incyte (INCY) Tops Q1 EPS by 12c
Mar 26, 2025 07:32AM Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
Mar 18, 2025 10:40AM Incyte (INCY) PT Lowered to $72 at Truist Following Povo Data
Mar 18, 2025 07:07AM William Blair Downgrades Incyte (INCY) to Market Perform
Mar 17, 2025 04:06PM Citi on Incyte (INCY): 'We are buyers on weakness'
Mar 17, 2025 03:30PM Incyte (INCY) PT Lowered to $75 at Jefferies
View More Recent Stories View Older Stories